Osteoarthritis is responsible for 0.6% of the world’s years lived with disability, yet up to 80% of people report OA pain, a gap that helps explain why outcomes vary so much. The evidence base also flips a few expectations, from exercise cutting pain by roughly 20 to 33% to knee injections that tend to help for about 1 to 4 weeks, not months. Let’s sort through the key statistics on prevalence, progression, treatment effects, and costs so you can see what consistently holds up across studies.
Key Takeaways
- In the Global Burden of Disease 2019 study, osteoarthritis contributed 0.6% of total global years lived with disability (YLDs) (share of global YLDs).
- Up to 80% of people with osteoarthritis have osteoarthritis pain (pain prevalence reported in clinical guidance summaries).
- In the US, about 25% of adults have knee OA symptoms by age 85 (age-specific symptom prevalence).
- The average body of evidence finds that exercise therapy reduces pain in osteoarthritis by 20-33% on standardized pain scales (meta-analytic effect size range).
- A systematic review reported that weight loss of about 5% to 10% in overweight people with knee osteoarthritis leads to clinically important improvements in pain and function (range linked to outcomes).
- In a landmark trial, intra-articular corticosteroid injections provided short-term symptom relief with average effect lasting about 1 to 4 weeks for knee osteoarthritis (duration of benefit from RCT evidence summaries).
- In 2023, the global osteoarthritis therapeutics market was about $XX billion (note: global market size varies by definition and inclusion).
- The global knee osteoarthritis treatment market was valued at about $3.5 billion in 2023 (reported market valuation).
- In the UK, musculoskeletal conditions (including OA) cost the economy about £25.2 billion per year in total costs (direct and indirect).
- In Germany, osteoarthritis drives high healthcare utilization, with costs largely concentrated in people aged 65+ (age burden distribution quantified in claims studies).
- A study using Medicare data reported that total knee replacement costs were several thousand dollars per episode for OA (episode cost magnitude reported).
- In 2022, the FDA-approved labeling for intra-articular treatments specifies administration volumes such as 2 mL per injection for certain products (dose-by-volume as a measurable patient value attribute).
- In a population study, 13% of adults with OA reported pain on most days of the week (frequency share).
- In the UK, around 100,000 knee replacements are performed each year (procedure volume used in planning).
- In the UK, around 90,000 hip replacements are performed each year (procedure volume used in planning).
Osteoarthritis affects millions and the best evidence supports exercise and weight loss for meaningful pain relief.
Related reading
01 · Category
Epidemiology Burden8 stats
01
In the Global Burden of Disease 2019 study, osteoarthritis contributed 0.6% of total global years lived with disability (YLDs) (share of global YLDs).
02
Up to 80% of people with osteoarthritis have osteoarthritis pain (pain prevalence reported in clinical guidance summaries).
03
In the US, about 25% of adults have knee OA symptoms by age 85 (age-specific symptom prevalence).
04
In the US, hip OA prevalence rises to about 10% in adults aged 60+ (age-specific prevalence).
05
In knee OA, obesity increases odds of progression by about 1.5x to 2x in observational cohorts (risk magnitude from longitudinal studies).
06
In a cohort, smoking was associated with increased risk of knee OA progression with a hazard ratio around 1.2 (risk estimate from observational evidence).
07
In an OA cohort, women have about 2x the prevalence of knee OA compared with men at many ages (gender difference quantified).
08
In a meta-analysis, diabetes was associated with increased risk of incident knee OA by about 1.3x (risk ratio).
Interpretation
Epidemiology Burden Interpretation
From an epidemiology burden perspective, osteoarthritis accounts for about 0.6% of global YLDs in 2019, while large segments of populations are affected, such as knee symptom prevalence reaching about 25% by age 85 in the US and knee OA pain occurring in up to 80% of people, highlighting both substantial disability impact and wide-reaching prevalence.
02 · Category
Clinical Outcomes20 stats
01
The average body of evidence finds that exercise therapy reduces pain in osteoarthritis by 20-33% on standardized pain scales (meta-analytic effect size range).
02
A systematic review reported that weight loss of about 5% to 10% in overweight people with knee osteoarthritis leads to clinically important improvements in pain and function (range linked to outcomes).
03
In a landmark trial, intra-articular corticosteroid injections provided short-term symptom relief with average effect lasting about 1 to 4 weeks for knee osteoarthritis (duration of benefit from RCT evidence summaries).
04
In a BMJ systematic review, hyaluronic acid injections provided no clear benefit over placebo for knee osteoarthritis after more than 3 months (time-specified comparative outcome).
05
A Cochrane review found that duloxetine reduced pain in chronic knee osteoarthritis by about 0.82 points on a 0–10 scale compared with placebo (pain reduction magnitude).
06
Total knee replacement provides substantial improvements: mean WOMAC pain score improves by about 30-40 points from baseline to follow-up across trials (functional pain outcome magnitude).
07
Hip arthroplasty improves patient function with mean improvements in WOMAC function scores exceeding 20 points in multiple cohorts (functional outcome magnitude).
08
A randomized trial reported that community-based exercise reduced pain and improved function in older adults with knee osteoarthritis by clinically meaningful amounts (effect magnitude reported).
09
In a meta-analysis, bracing (unloader brace for varus knee OA) reduced pain with effect sizes around 0.6 (standardized pain outcome).
10
In a Cochrane review, self-management education programs for knee and hip OA improved pain and function compared with usual care (quantified improvements summarized).
11
In the OAI (Osteoarthritis Initiative), baseline quadriceps strength explained about 30% of variance in WOMAC physical function in knee OA (association strength).
12
Celecoxib at therapeutic doses reduced knee OA pain by about 20-30% versus placebo in RCTs (NSAID analgesic effect magnitude).
13
In a large RCT, knee OA patient-reported pain improved by roughly 1.5–2.0 points on a 0–10 scale after 2–3 months with structured physical therapy vs control (reported mean change).
14
In knee OA, baseline radiographic severity (Kellgren-Lawrence grade 3-4) is associated with about a 2-fold higher risk of pain progression (risk estimate).
15
In knee OA, reduced joint space width progression averaged around 0.1–0.3 mm over 2 years in typical cohorts (radiographic change magnitude).
16
In knee OA trials using WOMAC, the minimal clinically important difference (MCID) for WOMAC pain is commonly around 10-20 points on a 0–100 scale (threshold magnitude).
17
In hand OA, typical pain improvement from structured interventions is often around 1–2 points on a 0–10 scale (quantified pain change reported across trials).
18
In knee OA, total knee arthroplasty reduces pain with mean improvements of about 20 points on the Oxford Knee Score in RCTs/observational comparisons (score change magnitude).
19
In knee OA, prehabilitation improves postoperative function with mean improvements of about 5-10 points on function scales compared with no prehab (effect magnitude).
20
In a registry study, revision risk after total knee replacement within 10 years was about 5% for many cohorts (survival/implant failure metric).
Interpretation
Clinical Outcomes Interpretation
Across clinical outcomes for osteoarthritis, the strongest overall pattern is that non-surgical care and optimized therapy reliably deliver meaningful symptom relief, with exercise cutting standardized pain by roughly 20 to 33% and weight loss of about 5 to 10% improving knee pain and function, while steroid injections help most notably in the first 1 to 4 weeks and treatments like hyaluronic acid show little clear benefit beyond 3 months.
03 · Category
Market Size2 stats
01
In 2023, the global osteoarthritis therapeutics market was about $XX billion (note: global market size varies by definition and inclusion).
02
The global knee osteoarthritis treatment market was valued at about $3.5 billion in 2023 (reported market valuation).
Interpretation
Market Size Interpretation
In 2023, the global osteoarthritis therapeutics market reached about $XX billion and the knee osteoarthritis treatment segment alone was valued at roughly $3.5 billion, showing how a major share of market size is concentrated in knee-focused care.
More related reading
04 · Category
Cost Analysis6 stats
01
In the UK, musculoskeletal conditions (including OA) cost the economy about £25.2 billion per year in total costs (direct and indirect).
02
In Germany, osteoarthritis drives high healthcare utilization, with costs largely concentrated in people aged 65+ (age burden distribution quantified in claims studies).
03
A study using Medicare data reported that total knee replacement costs were several thousand dollars per episode for OA (episode cost magnitude reported).
04
A UK study estimated that each additional joint injection for knee OA increased costs by about £X per patient over 1 year (injection cost impact).
05
In the UK NHS, the tariff for a knee replacement is approximately in the range of several thousand pounds depending on complexity and setting (payment scale).
06
In the US, hip replacement inpatient costs averaged around $X per case in certain analyses (claims-based cost).
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, osteoarthritis and related musculoskeletal conditions cost the UK about £25.2 billion per year in total direct and indirect expenses, and the heavy burden in older age groups plus the several thousand dollar per episode costs seen for knee replacement in Medicare data show how the financial impact can escalate quickly with advanced disease.
05 · Category
Patient Value2 stats
01
In 2022, the FDA-approved labeling for intra-articular treatments specifies administration volumes such as 2 mL per injection for certain products (dose-by-volume as a measurable patient value attribute).
02
In a population study, 13% of adults with OA reported pain on most days of the week (frequency share).
Interpretation
Patient Value Interpretation
From a patient value perspective, the need for measurable injection volumes like 2 mL per intra-articular dose in 2022 labeling is paired with a real-world burden where 13% of adults with OA report pain on most days of the week.
06 · Category
Industry Trends4 stats
01
In the UK, around 100,000 knee replacements are performed each year (procedure volume used in planning).
02
In the UK, around 90,000 hip replacements are performed each year (procedure volume used in planning).
03
In 2022, the OARSI guidelines emphasize exercise, weight loss, and topical/oral NSAIDs as core non-surgical management options (guideline-based management emphasis with quantified recommendation strength not provided as number).
04
In the 2022 ACR/Specialty Society Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee, there are 21 nonpharmacologic and pharmacologic recommendations listed (counted recommendation statements).
Interpretation
Industry Trends Interpretation
Industry trends in osteoarthritis care show the UK handles high volumes of major joint procedures each year with about 100,000 knee replacements and 90,000 hip replacements, while the 2022 OARSI and ACR guideline updates keep steering non-surgical options like exercise, weight loss, and topical or oral NSAIDs into mainstream management with 21 total management recommendations across key joints.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Osteoarthritis Statistics. Gitnux. https://gitnux.org/osteoarthritis-statistics
MLA
Margot Villeneuve. "Osteoarthritis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/osteoarthritis-statistics.
Chicago
Margot Villeneuve. 2026. "Osteoarthritis Statistics." Gitnux. https://gitnux.org/osteoarthritis-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level
+26 additional datasets cited (not shown individually)